Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The intracellular mature virion (IMV) is the primary infectious form of vaccinia virus, a poxvirus, characterized by a single lipid bilayer membrane with an asymmetric protein coat, enclosing a biconcave core containing the viral DNA genome and structural proteins such as A10, A4, A3, and L4. IMV forms from spherical immature virions (IV) through maturation steps including proteolysis, within cytoplasmic virus factories, and features surface proteins like A27L, D8L, H3L, A26L, A17L, A14L, and A13L involved in cell binding to glycosaminoglycans and laminin. Entry into host cells occurs at the plasma membrane via actin-dependent signaling involving rac1, rhoA, ezrin, tyrosine and PKC phosphorylation, delivering the uncoated core into the cytoplasm; IMV is less efficient than extracellular enveloped virus (EEV).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Vaccinia virus intracellular mature virion (IMV) (IMV).